Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Indications expanded for Ozempic and Rybelsus to reduce cardiovascular risk in adults with type 2 diabetes and known heart disease

News | Pharmaceuticals

FDA Clears Semaglutide For Cardiac Risk Reduction in Diabetic Patients

January 29, 2020 - The U.S. Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk's Ozempic ...

January 29, 2020

This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

News | Pharmaceuticals

Fruit Fly Hearts Show How to Keep Human Cardiac Muscle Young

January 9, 2020 – Researchers may have discovered a way to turn back the clock on aging heart muscles in fruit flies, a ...

January 09, 2020

$The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) from AstraZeneca and granted priority review for dapagliflozin (Farxiga) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D).$

News

Dapagliflozin Granted FDA Priority Review for Heart Failure With Reduced Ejection Fraction

January 7, 2020 — The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) ...

January 07, 2020

News | Pharmaceuticals

Study Finds Drug Therapy for High Triglycerides to Have a Sustained Effect Using Low Dosages

December 30, 2019 — A drug therapy targeting the production of a protein produced by the liver has led to sustained and ...

December 30, 2019

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies

FDA Clears First Generics for Eliquis

December 27, 2019 — The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of ...

December 27, 2019

Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.

Feature | Pharmaceuticals | Dave Fornell, Editor

FDA Expands Vascepa to Reduce Cardiovascular Events in Elevated Triglyceride Patients

December 16, 2019 — The U.S. Food and Drug Administration (FDA), on Dec. 13, approved the use of Vascepa (icosapent ...

December 16, 2019

News | Antiplatelet and Anticoagulation Therapies

Low-dose Aspirin May Not Help African Americans Prevent Heart Disease

December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African ...

December 12, 2019

News | Cardiovascular Clinical Studies

Virtual Study to Track Statin-Related Adverse Events Being Undertaken by University of Connecticut and Hartford Healthcare

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

November 26, 2019

Heart failure VICTORIA TrIal a success. Dave Fornell

News | Heart Failure

Investigational Drug Vericiguat Reduced the Risk of Heart Failure Hospitalization in VICTORIA Trial

November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of ...

November 21, 2019

In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff

Feature | AHA

ISCHEMIA Trial Results Find Interventions for Stable Heart Disease No better Than Drug Therapy

November 19, 2019 — After 12 years of collecting data, the results of the landmark ISCHEMIA (International Study of ...

November 19, 2019

Feature | AHA | Dave Fornell, Editor

American Heart Association 2019 Late-breaking Trials

November 19, 2019 — Here is a list of the key late-breaking clinical study presentations and links to the results at the ...

November 19, 2019

Cholesterol test prep blood draw needle stick from American Heart Association

News | AHA

ASCVD Patients Face Barriers Reaching Guideline-Recommended Cholesterol Goals

November 14, 2019 — A large majority of patients with atherosclerotic cardiovascular disease (ASCVD) in the NCDR ...

November 14, 2019

One of the cardiology technologies in the list of top advances in 2019 is Medtronic’s Tyrx Absorbable Antibacterial Envelope using to enclose cardiac implantable electronic devices (CIEDs). It reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, based on data presented at ACC 2019.

News

Cleveland Clinic Unveils Top 10 Medical Innovations for 2020

November 6, 2019 — Cleveland Clinic announced the Top 10 Medical Innovations for 2020 at a multimedia presentation last ...

November 06, 2019

EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment for structural heart procedures. #TCT2019 #TCT #TCT19

Feature | TCT | Dave Fornell, Editor

6 Hot Topics in Interventional Cardiology at TCT 2019

The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual Transca ...

November 04, 2019

Former National Football League (NFL) player Ed White (left) needed a new aortic heart valve but decided to wait several months for the FDA to approve TACR for low-risk patients so he would not have to undergo open heart surgery. Democratic presidential candidate Sen. Bernie Sanders received two stents after he was hospitalized with chest pain was hospitalized with chest pain on Oct. 1 in Las Vegas. The event brought PCI to the forefront of national news in October.

Feature | Dave Fornell, Editor

November 1, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) m ...

November 01, 2019